Background β-catenin plays a key role in the progression of colorectal cancer (CRC). However, its prognostic significance for patients with CRC remains controversial. Methodology Identical search strategies were used to search relevant literatures in the PubMed, Embase and Web of Science databases. The correlation between β-catenin expression and clinicopathological features and prognosis was analyzed. Principal Findings A total of 18 studies met the inclusion criteria, which comprised 3665 cases. Meta-analysis suggested that β-catenin overexpression in the nucleus was significantly associated with disease free survival (DFS) (n = 541 in 3 studies; HR = 1.87, 95% CI: 1.28–2.71; Z = 3.26; P = 0.001) and overall survival (OS) for CRC patients (n = 2630 in 10 studies; HR = 1.55, 95% CI: 1.12–2.14; Z = 2.62; P = 0.009). However, there was no significant association between β-catenin expression in the cytoplasm and OS (n = 1327 in 3 studies; HR = 1.04, 95% CI: 0.88–1.24, Z = 0.46, P = 0.643). The combined odds ratio (OR) of β-catenin in the nucleus indicated that β-catenin overexpression was associated with advanced stage CRC (n = 950 in 7 studies; OR = 0.71, 95% CI: 0.53–0.94; Z = 2.35; P = 0.019) and metastasis of CRC (n = 628 in 5 studies; OR = 0.49, 95% CI: 0.25–0.96, Z = 2.06, P = 0.039). β-catenin overexpression in the nucleus had no correlation with the tumor site (colon or rectum), differentiation grade, lymph node status or depth of invasion. The pooled ORs were 1.09 (95% CI: 0.41–2.91, Z = 0.18, P = 0.856), 1.27(95% CI: 0.76–2.10, Z = 0.92, P = 0.357), 0.71(95% CI: 0.46–1.09, Z = 1.58, P = 0.115) and 0.82(95% CI: 0.4–1.68, Z = 0.53, P = 0.594). Conclusions This study showed that β-catenin overexpression in the nucleus, rather than in the cytoplasm, appeared to be associated with progress disease and a worse prognosis for CRC patients.
References
[1]
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62: 10–29.
[2]
Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. New England Journal of Medicine 361: 2449–2460.
[3]
Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, et al. (2006) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology 24: 386–393.
[4]
Ricci-Vitiani L, Pagliuca A, Palio E, Zeuner A, De Maria R (2007) Colon cancer stem cells. Gut 57: 538–548.
[5]
O’Brien CA, Pollett A, Gallinger S, Dick JE (2006) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106–110.
[6]
Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP (2010) The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 9: 212.
[7]
de Sousa EM, Vermeulen L, Richel D, Medema JP (2011) Targeting Wnt signaling in colon cancer stem cells. Clinical Cancer Research 17: 647–653.
[8]
Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, et al. (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12: 468–476.
[9]
de Sousa EMF, Colak S, Buikhuisen J, Koster J, Cameron K, et al. (2011) Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 9: 476–485.
[10]
Maruyama K, Ochiai A, Akimoto S, Nakamura S, Baba S, et al. (2000) Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 59: 302–309.
[11]
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology 25: 603–605.
[12]
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 17: 2815–2834.
[13]
Handoll HH (2006) Systematic reviews on rehabilitation interventions. Archives of Physical Medicine and Rehabilitation 87: 875.
[14]
Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335: 914–916.
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 22: 719–748.
[17]
Andras C, Toth L, Molnar C, Tanyi M, Csiki Z, et al. (2012) Correlations between clinicopathological parameters and molecular signatures of primary tumors for patients with stage T3n0 colorectal adenocarcinomas: a single center retrospective study on 100 cases. Hepato-Gastroenterology 59: 1091–1097.
[18]
Toth L, Andras C, Molnar C, Tanyi M, Csiki Z, et al. (2012) Investigation of beta-catenin and E-cadherin expression in Dukes B2 stage colorectal cancer with tissue microarray method. Is it a marker of metastatic potential in rectal cancer? Pathology Oncology Research 18: 429–437.
[19]
Sun L, Hu H, Peng L, Zhou Z, Zhao X, et al. (2011) P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. American Journal of Pathology 179: 380–390.
[20]
Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, et al. (2011) Prognostic significance of Wnt-1, beta-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathology Oncology Research 17: 955–963.
[21]
Ozguven BY, Karacetin D, Kabukcuoglu F, Taskin T, Yener S (2011) Immunohistochemical study of E-cadherin and beta-catenin expression in colorectal carcinomas. Polish Journal of Pathology 62: 19–24.
[22]
Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, et al. (2011) Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 305: 1685–1694.
[23]
Matsuoka T, Mitomi H, Fukui N, Kanazawa H, Saito T, et al. (2011) Cluster analysis of claudin-1 and -4, E-cadherin, and beta-catenin expression in colorectal cancers. Journal of Surgical Oncology 103: 674–686.
[24]
Pancione M, Forte N, Fucci A, Sabatino L, Febbraro A, et al. (2010) Prognostic role of beta-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Human Pathology 41: 867–876.
[25]
Magnusson C, Mezhybovska M, Lorinc E, Fernebro E, Nilbert M, et al. (2010) Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. European Journal of Cancer 46: 826–835.
[26]
Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D, et al. (2009) Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Human Pathology 40: 714–725.
[27]
Togo N, Ohwada S, Sakurai S, Toya H, Sakamoto I, et al. (2008) Prognostic significance of BMP and activin membrane-bound inhibitor in colorectal cancer. World J Gastroenterol 14: 4880–4888.
[28]
Chen S, Liu J, Li G, Mo F, Xu X, et al. (2008) Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis. Scandinavian Journal of Gastroenterology 43: 456–464.
[29]
Martensson A, Oberg A, Jung A, Cederquist K, Stenling R, et al. (2007) Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncology Reports 17: 447–452.
[30]
Bravou V, Klironomos G, Papadaki E, Taraviras S, Varakis J (2006) ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. Journal of Pathology 208: 91–99.
[31]
Fernebro E, Bendahl PO, Dictor M, Persson A, Ferno M, et al. (2004) Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. International Journal of Cancer 111: 921–928.
[32]
Ougolkov AV, Yamashita K, Mai M, Minamoto T (2002) Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 122: 60–71.
[33]
Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, et al. (2001) Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clinical Cancer Research 7: 4013–4020.
[34]
Gough NR (2012) Focus issue: Wnt and beta-catenin signaling in development and disease. Sci Signal 5: eg2.
[35]
Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469–480.
[36]
Suh EK, Gumbiner BM (2003) Translocation of beta-catenin into the nucleus independent of interactions with FG-rich nucleoporins. Experimental Cell Research 290: 447–456.
[37]
Henderson BR (2000) Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2: 653–660.
[38]
Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, et al. (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382: 638–642.
[39]
Fuchs SY, Ougolkov AV, Spiegelman VS, Minamoto T (2005) Oncogenic beta-catenin signaling networks in colorectal cancer. Cell Cycle 4: 1522–1539.
[40]
Filiz AI, Senol Z, Sucullu I, Kurt Y, Demirbas S, et al. (2010) The survival effect of E-cadherin and catenins in colorectal carcinomas. Colorectal Dis 12: 1223–1230.
